- Home
- LFS vs PYXS Comparison
LFS vs PYXS Comparison
Compare LFS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.27
HOLD
Current Price
$1.51
Company Overview
Basic Information| Metric | LFS | PYXS |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 71.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFS | PYXS |
|---|---|---|
| Price | $2.27 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 372.0K | ★ 429.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,146,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $0.84 |
| 52 Week High | $12.49 | $5.55 |
Technical Indicators
Market Signals| Indicator | LFS | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 48.72 |
| Support Level | $2.22 | $1.27 |
| Resistance Level | $3.89 | $1.69 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 9.49 | 90.74 |
Price Performance
Historical Comparison LFS
PYXS
About LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.